Dogwood Therapeutics (DWTX) Cash from Financing Activities (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Cash from Financing Activities of $11.3 million for Q1 2026, up 53.16% year-over-year from $7.4 million in Q1 2025, and up 34577.45% quarter-over-quarter from $32561.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Cash from Financing Activities for 6 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 53.16% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.2 million (down 50.48% YoY), while the FY2025 annual figure was $7.3 million, down 56.39% from the prior year.
- Cash from Financing Activities rose to $11.3 million in Q1 2026 per DWTX's latest filing, from $32561.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $15.3 million in Q4 2024 and bottomed at -$120133.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $4.8 million across 4 years, with a median of $32561.0 in 2025.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 99.79% — and 2026, when it jumped 53.16%.
- Dogwood Therapeutics' Cash from Financing Activities stood at -$85995.0 in 2022, then surged by 17917.66% to $15.3 million in 2024, then sank by 99.79% to $32561.0 in 2025, then soared by 34577.45% to $11.3 million in 2026.
- Business Quant data shows DWTX's Cash from Financing Activities at $11.3 million in Q1 2026, $32561.0 in Q4 2025, and -$120133.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 23.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.29 Mn |
| Mar 31, 2026 | 11.29 Mn |
| Dec 31, 2025 | 32,561.00 |
| Dec 31, 2025 | 32,561.00 |
| Jun 30, 2025 | -120,133.00 |
| Jun 30, 2025 | -120,133.00 |
| Mar 31, 2025 | 7.37 Mn |
| Mar 31, 2025 | 7.37 Mn |
| Dec 31, 2024 | 15.32 Mn |
| Dec 31, 2024 | 15.32 Mn |
| Sep 30, 2024 | -70,227.00 |
| Sep 30, 2024 | -70,227.00 |
| Dec 31, 2022 | -85,995.00 |
| Dec 31, 2022 | -85,995.00 |
| Mar 31, 2021 | -97,604.00 |
| Mar 31, 2021 | -97,604.00 |
| Dec 31, 2020 | 31.58 Mn |
| Dec 31, 2020 | 31.58 Mn |
| Sep 30, 2020 | 9,480.00 |
| Sep 30, 2020 | 9,480.00 |